Summary
Andrew Stein is a Senior Director of Pharmacometrics at Novartis with 13 years of industry experience building mathematical and PK/PD models to inform drug development decisions. Trained as an applied mathematician (PhD Univ. of Michigan) with mechanical engineering degrees from MIT, he specializes in chronic myeloid leukemia, solid tumor growth, nonlinear mixed-effects modeling, and translational PKPD. He has progressed through technical and leadership roles at Novartis since 2005, pairing hands-on model development with strategic program support across preclinical and clinical stages. Known for translating complex biological data into actionable insights, he also has early research experience in collagen micromechanics and diagnostic tool development for Gleevec responsiveness. Based in Cambridge, MA, he combines deep quantitative rigor with pragmatic decision-focused communication across multidisciplinary teams.
13 years of coding experience
9 years of employment as a software developer
PhD Applied Mathematics, PhD Applied Mathematics at University of Michigan
SM Mechanical Engineering, SM Mechanical Engineering at Massachusetts Institute of Technology